Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 10, 1999, Pages 1329-1334

  Fabris, P ^a   Tositti, G ^a   Negro, F ^b   Marranconi, F ^c   Infantolino, D ^d   Rassu, M ^a   De Lalla, F ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c Hospital of Schio   (Italy)

^d Hospital of Castelfranco   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

KETOPROFEN; RANITIDINE; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ARTICLE; ASTHENIA; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; EPIGASTRIC PAIN; FEMALE; FEVER; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; KETOPROFEN; MALE; MIDDLE AGED;

EID: 0032826728     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00613.x     Document Type: Article

References (32)

1. 1 Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alpha-2b regimes for long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-62.
2. 2 Boucher E, Jouanolle H, André P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-7.
3. 3 Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Faruki H. A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. J Viral Hepat 1997; 4: 101-6.
4. 4 Beloqui O, Prieto J, Suarez M, et al. N-acetylcysteine enhances the response to interferon-alpha in chronic hepatitis C. A pilot study. J Interferon Res 1993; 13: 279-82.
5. 5 Reichard O, Norkrans G, Frydé NA, et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
6. 6 Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42: 1681-7.
7. 7 Okano T, Ari K, Shindo M. Efficacy of interferon combined glycyrrhizin in patients with chronic hepatitis C resistant to interferon therapy. Nippon Rinsho 1994; 52: 1823-7.
8. 8 Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin and interferon for the treatment of chronic hepatitis C infection: a randomised, placebo-controlled double-blind trial. Hepatology 1998; 27: 1128-35.
9. 9 Negro F, Male PJ, Perrin L, Giostra E, Hadengue A. Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone. J Hepatol 1998; 29: 369-74.
10. 10 Caldwell SH, Dickson RC, Driscoll C, Sue M, Yeaton P. A pilot study using piroxicam with interferon α 2b in the retreatment of refractory hepatitis C [abstract]. Gastroenterology 1995; 108: 1043A.
11. 11 Hannigan GE, Williams BRG. Signal transduction by interferon-alpha through arachidonic metabolism. Sci 1991; 251: 204-7.
12. 12 Tsuboi I, Tanaka H, Nakao M, Shichijo S, Itoh K. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down regulation of IL-6 production. Cytokine 1995; 7: 372-9.
13. 13 Baskin G. Interferon-signalling through arachidonic acid-dependent pathways: a clue to adjuvant therapy for chronic hepatitis? Hepatology 1991; 14: 392-4.
14. 14 Andreone P, Cursaro C, Gasbarrini G. Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993; 19: 228-31.
15. 15 Andreone P, Cursaro C, Gramenzi A, et al. Indomethacin enhaces serum 2′5′-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis infection. J Hepatol 1994; 21: 984-8.
16. 16 Glambartolomei S, Artini M, Almerighi C, Levrero M, Balsano C. Modulation of IFN-alpha signalling by NSAIDs: therapeutical implication in HCV patients [abstract]. J Hepatol 1998; 28(Suppl. 1): 103.
17. 17 Zarski JP, Maynard-Muet M, Chousterman S, et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998; 27: 862-7.
18. 18 Knodell RG, Ishak K, Black W, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymtomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
19. 19 Imberti L, Cariani E, Bettinardi A, Zonaro A, Albertini A, Primi D. An immunoassay for specific amplified HCV sequences. J Virol Meth 1991; 34: 233-43.
20. 20 Viasoz S, Zilbert A, Ramakrishnan K, et al. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Meth 1994; 48: 81-92.
21. 21 Detmer J, Lagier R, Flyn R, et al. Accurate quantification of hepatitis C virus RNA (HCV-RNA) from all HCV genotypes by using branched DNA technology. J Clin Microbiol 1996; 34: 901-7.
22. 22 Bellobuono A, Mondazzi L, Tempini S, et al. Should patients with early loss of serum HCV RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months? J Hepatol 1999; 30: 8-13.
23. 23 Andreone P, Gramenzi A, Cursaro C, et al. A randomised controlled trial of IFN α + ketoprofen or IFN α + Ribavirin in HCV chronic active hepatitis (CAH) non responder to IFN α alone [abstract]. Hepatology 1995; 22: 119A.
24. 24 Muñoz A, Levi D, Podestà A, et al. Evaluation of different doses of ketoprofen associated to interferon in the treatment of chronic hepatitis C. A prospective and randomized study [abstract]. Hepatology 1998; 28: 712A.
25. 25 Anderson FH, Zeng L, Yoshida EM, Rock NR. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol 1997; 11: 294-7.
26. 26 Nunes FA, Santoro J, Kaufman B, et al. Interferon-alpha and ribavirin alone or in combination with ketoprofen for the treatment of patients with chronic hepatitis C who have not responded to previous interferon therapy [abstract]. Hepatology 1998; 28: 579A.
27. 27 Di Costanzo GG, Ascione A, Lanza AG, Utech W, Capibianco G, Vacco C. Adjuvant therapy for interferon-resistant patients: do cycloxygenase inhibitors have any role? A pilot study. J Hepatol 1995; 23: 359-60.
28. 28 Giannelli G, Antonelli G, Fera G, Dianzani F, Schiraldi O. 2′,5′-oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J Interferon Res 1993; 13: 57-60.
29. 29 Pawlotsky JM, Hovanessian A, Roudot-Thoraval F, et al. Activity of the interferon-induced 2′,5′-oligoadenylate synthetase in patients with chronic hepatitis C. J Interfer Res 1995; 15: 857-62.
30. 30 Andreone P, Cursaro C, Gramenzi A, et al. Modulation of Th1/Th2 cytokine profile and antiviral response by interferon a (IFNa) and non steroidal anti-inflammatory drugs (NSAIDs) in hepatitis C virus (HCV) [abstract]. Hepatology 1997; 26: 410A.
31. 31 Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(Suppl. 1): 122S-7S.
32. 32 Marchetto S, Fabbri C, Mazzeo C, et al. Cocktail therapy for chronic hepatitis C preliminary results [abstract]. Hepatology 1998; 28: 211A.